{"id":"comparator-niacin-laropiprant","safety":{"commonSideEffects":[{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL426559","moleculeType":"Small molecule","molecularWeight":"435.90"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Niacin (vitamin B3) is a lipid-modifying agent that increases HDL cholesterol and decreases triglycerides and LDL cholesterol through multiple pathways including reduced hepatic VLDL production. Laropiprant is a selective antagonist of the prostaglandin D2 receptor (DP1), which mediates the vasodilatory flushing response that limits niacin tolerability. The combination allows higher niacin doses with improved tolerability.","oneSentence":"Niacin raises HDL cholesterol and lowers triglycerides, while laropiprant blocks the prostaglandin D2 receptor to reduce niacin-induced flushing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:43:29.714Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia in patients at risk for cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT00769132","phase":"PHASE1","title":"A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08-03","conditions":"Hypercholesterolemia","enrollment":26},{"nctId":"NCT00479882","phase":"PHASE3","title":"MK-0524B Lipid Study (MK-0524B-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-15","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":2414},{"nctId":"NCT00533312","phase":"PHASE2","title":"MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":"Hypercholesterolemia","enrollment":407},{"nctId":"NCT00269217","phase":"PHASE3","title":"Lipid Efficacy Study (0524B-022)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":1400},{"nctId":"NCT00111891","phase":"PHASE2","title":"An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06","conditions":"Dyslipidemia","enrollment":575},{"nctId":"NCT01012219","phase":"PHASE1","title":"A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":36},{"nctId":"NCT00485758","phase":"PHASE3","title":"Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Diabetes Mellitus Type 2","enrollment":796},{"nctId":"NCT00384293","phase":"PHASE3","title":"Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-09","conditions":"Hypercholesterolemia, Familial","enrollment":937},{"nctId":"NCT00618995","phase":"PHASE1","title":"A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08","conditions":"Type 2 Diabetes Mellitus","enrollment":26},{"nctId":"NCT00536510","phase":"PHASE3","title":"Effect of MK0524A on Cholesterol Levels (0524A-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hypercholesterolemia, Hyperlipidemia","enrollment":646},{"nctId":"NCT00536237","phase":"PHASE2","title":"MK0524A Phase IIb Study (0524A-011)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-08","conditions":"Flushing","enrollment":154},{"nctId":"NCT00944645","phase":"PHASE1","title":"MK0524A Bioequivalence Study (0524A-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10","conditions":"Dyslipidemia","enrollment":188},{"nctId":"NCT00479388","phase":"PHASE3","title":"Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1216}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK0524A"],"phase":"phase_3","status":"active","brandName":"Comparator: niacin + laropiprant","genericName":"Comparator: niacin + laropiprant","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Niacin raises HDL cholesterol and lowers triglycerides, while laropiprant blocks the prostaglandin D2 receptor to reduce niacin-induced flushing. Used for Dyslipidemia in patients at risk for cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}